Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection

Journal of General Virology

Volumn 89, Issue 1, 2008, Pages 250-260

  Mapletoft, John W ^a   Oumouna, Mustapha ^a,b   Kovacs Nolan, Jennifer ^a   Latimer, Laura ^a   Mutwiri, George ^a   Babiuk, Lorne A ^a   van Drunen Littel van den Hurk, Sylvia ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF BLIDA   (Algeria)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; FORMALDEHYDE; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INACTIVATED VACCINE; INTERLEUKIN 5; NEUTRALIZING ANTIBODY; POLYMER; POLYPHOSPHAZENE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SINGLE DRUG DOSE; SPLEEN CELL; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS REPLICATION;

ADMINISTRATION, INTRANASAL; ANIMALS; BASE SEQUENCE; DINUCLEOSIDE PHOSPHATES; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTERFERON TYPE II; INTERLEUKIN-5; LUNG; MICE; OLIGODEOXYRIBONUCLEOTIDES; ORGANOPHOSPHORUS COMPOUNDS; POLYMERS; RETROVIRIDAE INFECTIONS; SPLEEN; SPUMAVIRUS; VACCINES, INACTIVATED; VIRAL VACCINES;

BOVINE RESPIRATORY SYNCYTIAL VIRUS; MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 38349050374     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.83300-0     Document Type: Article

References (52)

1. Almeida, R. S., Domingues, H. G., Coswig, L. T., D'Arce, R. C., de Carvalho, R. F. & Arns, C. W. (2004). Detection of bovine respiratory syncytial virus in experimentally infected balb/c mice. Vet Res 35, 189-197.
2. Andrianov, A. K., Svirkin, Y. Y. & LeGolvan, M. P. (2004). Synthesis and biologically relevant properties of polyphosphazene polyacids. Biomacromolecules 5, 1999-2006.
3. Baca-Estrada, M. E., Snider, M., Tikoo, S. K., Harland, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (1996). Immunogenicity of bovine herpesvirus 1 glycoprotein D in mice: effect of antigen form on the induction of cellular and humoral immune responses. Viral Immunol 9, 11-22.
4. Ballas, Z. K., Rasmussen, W. L. & Krieg, A. M. (1996). Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157, 1840-1845.
5. Cano, F., Plotnicky-Gilquin, H., Nguyen, T. N., Liljeqvist, S., Samuelson, P., Bonnefoy, J., Stahl, S. & Robert, A. (2000). Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides. Vaccine 18, 2743-2752.
6. Chin, J., Magoffin, R. L., Shearer, L. A., Schieble, J. H. & Lennette, E. H. (1969). Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 89, 449-463.
7. Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V. & Harding, C. V. (1997). CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186, 1623-1631.
8. + T cells. J Virol 66, 7444-7451.
9. Connors, M., Giese, N. A., Kulkarni, A. B., Firestone, C. Y., Morse, H. C., III & Murphy, B. R. (1994). Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 68, 5321-5325.
10. Corpet, F. (1988). Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 16, 10881-10890.
11. Davis, H. L., Weeratna, R., Waldschmidt, T. J., Tygrett, L., Schorr, J. & Krieg, A. M. (1998). CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160, 870-876.
12. Dumais, N., Patrick, A., Moss, R. B., Davis, H. L. & Rosenthal, K. L. (2002). Mucosal immunization with inactivated human immuno-deficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J Infect Dis 186, 1098-1105.
13. Etchart, N., Baaten, B., Andersen, S. R., Hyland, L., Wong, S. Y. & Hou, S. (2006). Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge. Eur J Immunol 36, 1136-1144.
14. Falcone, V., Mihm, D., Neumann-Haefelin, D., Costa, C., Nguyen, T., Pozzi, G. & Ricci, S. (2006). Systemic and mucosal immunity to respiratory syncytial virus induced by recombinant Streptococcus gordonii surface-displaying a domain of viral glycoprotein G. FEMS Immunol Med Microbiol 48, 116-122.
15. Fulginiti, V. A., Eller, J. J., Sieber, O. F., Joyner, J. W., Minamitani, M. & Meiklejohn, G. (1969). Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 89, 435-448.
16. Gallichan, W. S., Woolstencroft, R. N., Guarasci, T., McCluskie, M. J., Davis, H. L. & Rosenthal, K. L. (2001). Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 166, 3451-3457.
17. Hartmann, G. & Krieg, A. M. (2000). Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 164, 944-953.
18. Hartmann, G., Weeratna, R. D., Ballas, Z. K., Payette, P., Blackwell, S., Suparto, I., Rasmussen, W. L., Waldschmidt, M., Sajuthi, D. & other authors (2000). Delineation of a CpG phosphorothioate oligodeoxy-nucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164, 1617-1624.
19. Heilman, C. A. (1990). From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses. J Infect Dis 161, 402-406.
20. Ioannou, X. P., Gomis, S. M., Karvonen, B., Hecker, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (2002). CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine 21, 127-137.
21. Jakob, T., Walker, P. S., Krieg, A. M., Udey, M. C. & Vogel, J. C. (1998). Activation of cutaneous dendritic cells by CpG-containing oligodeoxy-nucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 161, 3042-3049.
22. Kahn, J. S., Roberts, A., Weibel, C., Buonocore, L. & Rose, J. K. (2001). Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 75, 11079-11087.
23. Kim, H. W., Canchola, J. G., Brandt, C. D., Pyles, G., Chanock, R. M., Jensen, K. & Parrott, R. H. (1969). Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89, 422-434.
24. Leader, S. & Kohlhase, K. (2003). Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 143, S127-S132.
25. Logan, A. C., Chow, K. P., George, A., Weinstein, P. D. & Cebra, J. J. (1991). Use of Peyer's patch and lymph node fragment cultures to compare local immune responses to Morganella morganii. Infect Immun 59, 1024-1031.
26. Mapletoft, J. W., Oumouna, M., Townsend, H. G., Gomis, S., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (2006). Formulation with CpG oligodeoxynucleotides increases cellular immunity and protection induced by vaccination of calves with formalin-inactivated bovine respiratory syncytial virus. Virology 353, 316-323.
27. Matsuoka, T., Okamoto, Y., Matsuzaki, Z., Endo, S., Ito, E., Tsutsumi, H., Williamson, R. A., Sakurai, H., Burton, D. R. & Saito, I. (2002). Characteristics of immunity induced by viral antigen or conferred by antibody via different administration routes. Clin Exp Immunol 130, 386-392.
28. McCluskie, M. J. & Davis, H. L. (1998). CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 161, 4463-4466.
29. McCluskie, M. J. & Davis, H. L. (2000). Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 19, 413-422.
30. McNeal, M. M., Rae, M. N. & Ward, R. L. (1999). Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine 17, 1573-1580.
31. Mutwiri, G., Benjamin, P., Soita, H., Townsend, H., Yost, R., Roberts, B., Andrianov, A. K. & Babiuk, L. A. (2007). Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine 25, 1204-1213.
32. Openshaw, P. J., Clarke, S. L. & Record, F. M. (1992). Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol 4, 493-500.
33. Oumouna, M., Mapletoft, J. W., Karvonen, B. C., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (2005). Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immuno-pathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine. J Virol 79, 2024-2032.
34. Paramore, L. C., Ciuryla, V., Ciesla, G. & Liu, L. (2004). Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 22, 275-284.
35. Payne, L. G. & Andrianov, A. K. (1998). Protein release from polyphosphazene matrices. Adv Drug Deliv Rev 31, 185-196.
36. Payne, L. G., Jenkins, S. A., Andrianov, A. & Roberts, B. E. (1995). Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Pharm Biotechnol 6, 473-493.
37. Payne, L. G., Jenkins, S. A., Woods, A. L., Grund, E. M., Geribo, W. E., Loebelenz, J. R., Andrianov, A. K. & Roberts, B. E. (1998). Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immuno-adjuvant for an influenza vaccine. Vaccine 16, 92-98.
38. Philippou, S., Otto, P., Reinhold, P., Elschner, M. & Streckert, H. J. (2000). Respiratory syncytial virus-induced chronic bronchiolitis in experimentally infected calves. Virchows Arch 436, 617-621.
39. Prince, G. A., Mond, J. J., Porter, D. D., Yim, K. C., Lan, S. J. & Klinman, D. M. (2003). Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J Virol 77, 13156-13160.
40. Roberts, T. L., Sweet, M. J., Hume, D. A. & Stacey, K. J. (2005). Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J Immunol 174, 605-608.
41. Stott, E. J. & Taylor, G. (1985). Respiratory syncytial virus. Brief review. Arch Virol 84, 1-52.
42. Stott, E. J., Ball, L. A., Young, K. K., Furze, J. & Wertz, G. W. (1986). Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge. J Virol 60, 607-613.
43. Stott, E. J., Taylor, G., Ball, L. A., Anderson, K., Young, K. K., King, A. M. & Wertz, G. W. (1987). Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol 61, 3855-3861.
44. Tebbey, P. W., Unczur, C. A., LaPierre, N. A. & Hancock, G. E. (1999). A novel and effective intranasal immunization strategy for respiratory syncytial virus. Viral Immunol 12, 41-45.
45. Tebbey, P. W., Scheuer, C. A., Peek, J. A., Zhu, D., LaPierre, N. A., Green, B. A., Phillips, E. D., Ibraghimov, A. R., Eldridge, J. H. & Hancock, G. E. (2000). Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H. Vaccine 18, 2723-2734.
46. Teloni, R., von Hunolstein, C., Mariotti, S., Donati, S., Orefici, G. & Nisini, R. (2004). Antibody classes & subclasses induced by mucosal immunization of mice with Streptococcus pyogenes M6 protein & oligodeoxynucleotides containing CpG motifs. Indian J Med Res 119 (Suppl.), 126-130.
47. Vollmer, J., Janosch, A., Laucht, M., Ballas, Z. K., Schetter, C. & Krieg, A. M. (2002). Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev 12, 165-175.
48. Walsh, E. E. (1993). Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice. Vaccine 11, 1135-1138.
49. Waris, M. E., Tsou, C., Erdman, D. D., Zaki, S. R. & Anderson, L. J. (1996). Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivatcd virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 70, 2852-2860.
50. Waris, M. E., Tsou, C., Erdman, D. D., Day, D. B. & Anderson, L. J. (1997). Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV. J Virol 71, 6935-6939.
51. Weibel, R. E., Stokes, J., Jr, Leagus, M. B., Mascoli, C. C. & Hilleman, M. R. (1966). Respiratory virus vaccines. V. Field evaluation for efficacy of heptavalent vaccine. Am Rev Respir Dis 94, 362-379.
52. Wu, J. Y., Wade, W. F. & Taylor, R. K. (2001). Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice. Infect Immun 69, 7695-7702.